These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22003835)

  • 1. The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer.
    Greenaway JB; Koehler A; McCulloch CA; Petrik J; Brown TJ; Ringuette MJ
    Biochem Cell Biol; 2012 Feb; 90(1):96-107. PubMed ID: 22003835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of the ovarian cancer microenvironment by SPARC.
    Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
    Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
    Greenaway J; Moorehead R; Shaw P; Petrik J
    Gynecol Oncol; 2008 Feb; 108(2):385-94. PubMed ID: 18036641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer.
    Brown TJ; Shaw PA; Karp X; Huynh MH; Begley H; Ringuette MJ
    Gynecol Oncol; 1999 Oct; 75(1):25-33. PubMed ID: 10502421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
    Said N; Motamed K
    Am J Pathol; 2005 Dec; 167(6):1739-52. PubMed ID: 16314484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
    Puolakkainen PA; Brekken RA; Muneer S; Sage EH
    Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.
    Bull Phelps SL; Carbon J; Miller A; Castro-Rivera E; Arnold S; Brekken RA; Lea JS
    Am J Obstet Gynecol; 2009 Feb; 200(2):180.e1-7. PubMed ID: 18992864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells.
    Mok SC; Chan WY; Wong KK; Muto MG; Berkowitz RS
    Oncogene; 1996 May; 12(9):1895-901. PubMed ID: 8649850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy.
    Sanches R; Kuiper M; Penault-Llorca F; Aunoble B; D'Incan C; Bignon YJ
    Cancer Gene Ther; 2000 May; 7(5):707-20. PubMed ID: 10830718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.
    Shaw TJ; Senterman MK; Dawson K; Crane CA; Vanderhyden BC
    Mol Ther; 2004 Dec; 10(6):1032-42. PubMed ID: 15564135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
    PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.
    Paley PJ; Goff BA; Gown AM; Greer BE; Sage EH
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):336-41. PubMed ID: 10985890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced angiogenesis characteristic of SPARC-null mice disappears with age.
    Reed MJ; Bradshaw AD; Shaw M; Sadoun E; Han N; Ferara N; Funk S; Puolakkainen P; Sage EH
    J Cell Physiol; 2005 Sep; 204(3):800-7. PubMed ID: 15795937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPARC enhances tumor stroma formation and prevents fibroblast activation.
    Chlenski A; Guerrero LJ; Yang Q; Tian Y; Peddinti R; Salwen HR; Cohn SL
    Oncogene; 2007 Jul; 26(31):4513-22. PubMed ID: 17260013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium.
    Gotoh N; Perdue NR; Matsushima H; Sage EH; Yan Q; Clark JI
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4679-87. PubMed ID: 17898292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
    Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire.
    Clark CJ; Sage EH
    J Cell Biochem; 2008 Jun; 104(3):721-32. PubMed ID: 18253934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer.
    Janát-Amsbury MM; Yockman JW; Anderson ML; Kieback DG; Kim SW
    Anticancer Res; 2006; 26(4B):2785-9. PubMed ID: 16886597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.